The revised and up-to-date third edition of Drug Interactions in Infectious Diseases delivers a text that will enhance your clinical knowledge of the complex mechanisms, risks, and consequences of drug interactions associated with antimicrobials, infection, and inflammation. The third edition features five new chapters that cover material not addressed in previous editions. These new chapters describe interactions with a number of drug classes such as non-HIV antiviral, antimalarial, antiparasitic, antihelmintic, macrolide, azalide and ketolide agents. A novel chapter on probe cocktail studies has been included to highlight an important research tool for drug development. These chapters address material that cannot be retrieved easily in the medical literature. The highly acclaimed food-drug interactions as well as the study design and analysis chapters remain definitive references. The newly written drug-cytokine interaction highlights the need for our improved understanding of the complex interrelationship of acute infection, inflammation, and the risk of drug interactions. Informative tables on specific drug-drug interactions are provided throughout the chapters as a quick clinical resource. The Third Edition of Drug Interactions in Infectious Diseases is a distillation of relevant drug interactions associated with antimicrobials, infection, and inflammation. This concise review of the mechanisms and strategies to manage drug interactions should be valuable to all health care practitioners. Features • Definitive reference source of up-to-date information on antimicrobial drug interactions • Informative tables on the degree of interaction for specific antimicrobial agents • In-depth discussion of mechanisms and potential mechanistic pathways of interaction • New chapters on non-HIV antiviral, antimalarial, antiparasitic, and macrolide, azalide and ketolide agents • New chapter on probe-cocktail studies as a research tool to study drug-drug interactions • Inclusion of new antimicrobial agents and their associated drug interactions • First rate chapters on study design and analysis, and drug-food interactions • A fresh perspective on drug-cytokine interactions • Authoritative chapter on regulatory considerations of drug interactions during drug development

The number and complexity of possible adverse drug interactions in the treatment of infectious diseases has grown significantly in recent years, not only because of the many new drugs, but also because patients with complex diseases are often being treated with multidrug regimens. In Drug Interactions in Infectious Disease, leading experts in antimicrobial pharmacology comprehensively review-and summarize for rapid access-important drug interactions that occur in the treatment of infectious diseases. The authors explain the mechanisms of drug-drug and drug-food interactions, examine their clinical significance and consequences, and detail practical clinical approaches to their management. Numerous patient case studies bring the data into perspective and illuminate critical interactions. The design, conduct, and data analysis of drug interaction studies is also outlined for clinicians involved in research. Comprehensive and highly practical, Drug Interactions in Infectious Disease offers health care professionals treating infectious diseases in their daily practice a comprehensive source of quickly accessible information about drug interaction problems, their mechanisms of action, and the best strategies for their management in busy patient care.

Over the past 25 years, the world’s population has witnessed an explosion in kno- edge about infectious diseases. The global population is coming to the realization that diseases long recognized to cause substantial suffering, such as malaria, tuberculosis, schistosomiasis, and hepatitis, can be diagnosed and treated, and that transmission can be prevented using tools that are available, and which may be becoming increasingly affordable. The global population is recognizing that few infections are local: the travel of humans, other animals, insects, and food transport pathogens around the world, often with astonishing rapidity. New pathogens are appearing, either newly recognized or newly developing, such as severe acute respiratory syndrome (SARS), avian inf- enza, metapneumovirus, or hepatitis C, which are causing human morbidity and m- tality. Finally, there is growing fear that dangerous pathogens may be intentionally introduced into human populations by deranged individuals or terrorist organizations. The potential to use drugs or biologic agents to treat and prevent infectious diseases has increased dramatically over the past quarter century as we have learned more about the biology of many of these agents, and as we have developed techniques to discover new agents by high throughput screening programs and by sophisticated drug design and synthesis.

THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad.

Over the years a number of excellent books have classified and detailed drug drug interactions into their respective categories, e.g. interactions at plasma protein binding sites; those altering intestinal absorption or bioavailability; those involving hepatic metabolising enzymes; those involving competition or antagonism for receptor sites, and drug interactions modifying excretory mechanisms. Such books have presented extensive tables of interactions and their management. Although of considerable value to clinicians, such publica tions have not, however, been so expressive about the individual mechanisms that underlie these interactions. It is within this sphere of "mechanisms" that this present volume specialises. It deals with mechanisms of in vitro and in vivo, drug-drug, drug food and drug-herbals interactions and those that cause drugs to interfere with diagnostic laboratory tests. We believe that an explanation of the mechanisms of such interactions will enable practitioners to understand more fully the nature of the interactions and thus enable them to manage better their clinical outcome. If mechanisms of interactions are better understood, then it may be pos sible for the researcher to develop meaningful animal/biochemical/tissue cul ture or physicochemical models to which new molecules could be exposed during their development stages. The present position, which largely relies on patients experiencing adverse interactions before they can be established or documented, can hardly be regarded as satisfactory. This present volume is classified into two major parts; firstly, pharmacoki netic drug interactions and, secondly, pharmacodynamic drug interactions.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and care. This edition updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015, shared at the end of 2015, and now published in full in 2016. It is being published in a changing global context for HIV and for health more broadly.